NYSE:HAE - Haemonetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.80
  • Forecasted Upside: 9.21 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$73.07
▼ -0.53 (-0.72%)

This chart shows the closing price for HAE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haemonetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HAE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HAE

Analyst Price Target is $79.80
▲ +9.21% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $79.80, with a high forecast of $90.00 and a low forecast of $59.00. The average price target represents a 9.21% upside from the last price of $73.07.

This chart shows the closing price for HAE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Haemonetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2022Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $74.00Low
8/11/2022JMP SecuritiesBoost Price TargetMarket Outperform$80.00 ➝ $90.00Low
8/11/2022Barrington ResearchBoost Price TargetOutperform$77.00 ➝ $88.00Low
8/11/2022Raymond JamesBoost Price TargetOutperform$76.00 ➝ $88.00Low
7/8/2022JMP SecuritiesReiterated RatingBuy$80.00N/A
7/1/2022Morgan StanleyBoost Price TargetEqual Weight$60.00 ➝ $70.00Low
7/1/2022Raymond JamesBoost Price TargetOutperform$63.00 ➝ $76.00Low
6/2/2022JMP SecuritiesReiterated RatingBuy$80.00High
5/11/2022Barrington ResearchBoost Price Target$71.00 ➝ $77.00High
2/9/2022Barrington ResearchReiterated RatingOutperformMedium
2/9/2022Raymond JamesLower Price TargetOutperform$70.00 ➝ $66.00Low
1/27/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
1/7/2022Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $60.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$75.00 ➝ $59.00High
11/10/2021JMP SecuritiesLower Price TargetOutperform$90.00 ➝ $80.00Medium
11/10/2021Raymond JamesLower Price TargetOutperform$75.00 ➝ $70.00Medium
6/29/2021Needham & Company LLCReiterated RatingBuy$86.00Low
6/17/2021CitigroupInitiated CoverageBuyHigh
5/20/2021JMP SecuritiesLower Price TargetMarket Outperform$110.00 ➝ $90.00Low
5/14/2021Jefferies Financial GroupLower Price TargetBuy$105.00 ➝ $85.00High
5/14/2021CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
5/14/2021Barrington ResearchLower Price TargetOutperform$91.00 ➝ $71.00High
5/14/2021Morgan StanleyLower Price TargetEqual Weight$83.00 ➝ $75.00High
5/14/2021JMP SecuritiesLower Price TargetOutperform$110.00 ➝ $90.00High
4/26/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$147.00 ➝ $83.00N/A
4/20/2021Barrington ResearchLower Price TargetOutperform$140.00 ➝ $91.00High
4/20/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$147.00 ➝ $83.00High
4/19/2021Needham & Company LLCLower Price TargetBuy$158.00 ➝ $108.00High
4/19/2021CJS SecuritiesDowngradeOutperform ➝ Market PerformHigh
2/12/2021Raymond JamesBoost Price TargetOutperform$145.00 ➝ $155.00Low
2/3/2021Morgan StanleyBoost Price TargetOverweight$139.00 ➝ $147.00Low
2/3/2021Raymond JamesBoost Price TargetOutperform$135.00 ➝ $145.00Low
2/3/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$140.00Low
1/21/2021JMP SecuritiesBoost Price Target$110.00 ➝ $140.00Medium
1/21/2021Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
1/20/2021Needham & Company LLCBoost Price TargetBuy$122.00 ➝ $142.00Medium
1/7/2021Raymond JamesBoost Price TargetOutperform$130.00 ➝ $135.00N/A
12/15/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $139.00Low
11/5/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$106.00High
11/2/2020Raymond JamesBoost Price TargetOutperform$100.00 ➝ $130.00Low
9/15/2020Barrington ResearchReiterated RatingHoldLow
9/8/2020Raymond JamesBoost Price TargetOutperform$93.00 ➝ $100.00Medium
8/5/2020Raymond JamesLower Price TargetOutperform$113.00 ➝ $93.00Low
8/4/2020Needham & Company LLCReiterated RatingBuy$119.00Low
7/8/2020Morgan StanleyLower Price TargetOverweight$138.00 ➝ $110.00Medium
7/1/2020Raymond JamesLower Price TargetOutperform$125.00 ➝ $113.00Low
5/29/2020Needham & Company LLCInitiated CoverageBuy$132.00Low
5/6/2020Raymond JamesLower Price TargetOutperform$130.00 ➝ $125.00High
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
5/5/2020Needham & Company LLCLower Price TargetBuy$142.00 ➝ $132.00High
4/7/2020Raymond JamesLower Price TargetOutperform$150.00 ➝ $130.00High
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
3/27/2020Morgan StanleyLower Price TargetOverweight$148.00 ➝ $138.00Low
2/5/2020Raymond JamesBoost Price TargetOutperform$145.00 ➝ $150.00High
2/4/2020Needham & Company LLCReiterated RatingBuy$142.00High
1/23/2020Raymond JamesLower Price TargetOutperform$150.00 ➝ $145.00High
1/10/2020Needham & Company LLCInitiated CoverageBuy$138.00Low
11/4/2019Barrington ResearchReiterated RatingBuy$141.00Low
8/7/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Low
8/7/2019Morgan StanleyBoost Price TargetOverweight$128.00 ➝ $148.00Low
8/7/2019Raymond JamesBoost Price TargetOutperform$110.00 ➝ $150.00Low
8/7/2019JMP SecuritiesBoost Price TargetOutperform$145.00Low
8/2/2019Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $140.00Low
5/14/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$110.00High
5/8/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$112.00 ➝ $116.00Low
2/6/2019Barrington ResearchBoost Price TargetOutperform ➝ Positive$112.00Low
10/5/2018Barrington ResearchReiterated RatingBuy$127.00High
8/9/2018Barrington ResearchBoost Price TargetOutperform$90.00 ➝ $118.00Low
8/8/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $120.00Low
8/7/2018Jefferies Financial GroupReiterated RatingBuy$125.00Medium
6/14/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$95.00 ➝ $110.00Low
5/9/2018Barrington ResearchBoost Price TargetOutperform$90.00Low
5/9/2018Jefferies Financial GroupBoost Price TargetBuy$95.00Low
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $100.00Low
2/7/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
2/7/2018Barrington ResearchReiterated RatingOutperform ➝ Outperform$57.00 ➝ $71.00High
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00High
2/7/2018Jefferies Financial GroupReiterated RatingBuy$80.00High
1/8/2018Jefferies Financial GroupBoost Price TargetTop Pick ➝ Buy$18.00 ➝ $75.00Low
1/2/2018Raymond JamesUpgradeUnderperform ➝ Market PerformHigh
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$51.00High
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$43.00 ➝ $51.00N/A
11/8/2017Craig HallumReiterated RatingHold$40.00 ➝ $50.00N/A
11/8/2017Barrington ResearchBoost Price TargetOutperform$48.00 ➝ $57.00N/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$38.00 ➝ $43.00N/A
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/13/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/12/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/14/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/13/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/13/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/12/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 4 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/11/2022

Current Sentiment

  • 4 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Haemonetics logo
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $73.07
Low: $72.43
High: $74.85

50 Day Range

MA: $65.59
Low: $59.28
High: $73.60

52 Week Range

Now: $73.07
Low: $43.50
High: $77.08

Volume

494,711 shs

Average Volume

508,903 shs

Market Capitalization

$3.75 billion

P/E Ratio

86.99

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Haemonetics?

The following equities research analysts have issued research reports on Haemonetics in the last twelve months: Barrington Research, Citigroup Inc., JMP Securities, Morgan Stanley, Needham & Company LLC, Raymond James, and StockNews.com.
View the latest analyst ratings for HAE.

What is the current price target for Haemonetics?

5 Wall Street analysts have set twelve-month price targets for Haemonetics in the last year. Their average twelve-month price target is $79.80, suggesting a possible upside of 9.2%. JMP Securities has the highest price target set, predicting HAE will reach $90.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $59.00 for Haemonetics in the next year.
View the latest price targets for HAE.

What is the current consensus analyst rating for Haemonetics?

Haemonetics currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HAE will outperform the market and that investors should add to their positions of Haemonetics.
View the latest ratings for HAE.

What other companies compete with Haemonetics?

How do I contact Haemonetics' investor relations team?

Haemonetics' physical mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier's listed phone number is (781) 848-7100 and its investor relations email address is [email protected] The official website for Haemonetics is www.haemonetics.com. Learn More about contacing Haemonetics investor relations.